Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2021
Clovis Oncology prepares $75 million stock sale
Clovis Oncology said late Monday that it would offer up to $75 million in new stock at market prices, with proceeds intended for general corporate purposes, debt service, and marketing and development of its lead drug Rubraca.
2020
FDA approves Rubraca for a prostate cancer subset
The FDA granted accelerated approval to rucaparib (Rubraca) for men with BRCA-mutated metastatic castration-resistant prostate cancer who had previously received an androgen receptor-directed therapy and taxane-based chemotherapy.
2019
Clovis Oncology and 3B Pharmaceuticals enter licensing and collaboration agreement
Clovis Oncology and 3B Pharmaceuticals entered into a global licensing and collaboration agreement covering development of an FAP-targeted radiopharmaceutical programme and discovery work on three additional targets. Clovis obtained U.S. and global rights excluding Europe for the initial programme, while 3B Pharmaceuticals retained European rights.